Please login to the form below

Not currently logged in
Email:
Password:

Novartis cuts manufacturing jobs in Switzerland and UK

Cuts include closure of Grimsby site by 2020

Novartis

Novartis is to cut 1,700 jobs in Switzerland and around 400 jobs with the closure of its longstanding manufacturing facility in Grimsby, England.

The company announced the cuts today as part of a global programme first begun in 2016 to lower production costs and improve profitability.

Chief executive Vas Narasimhan says the cuts are part of Novartis’ strategy to move away from high-volume drug production towards more specialised and personalised medicines.

This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as Novartis’ CAR-T drug Kymriah.

The company is currently struggling to scale up its CAR-T production worldwide, and wants to divert more investment into the technology.

The company says it has already invested more than $1bn in new production technologies in Switzerland such as its Schweizerhalle facility in Basel, which includes a continuous production plant, cell and gene therapy production facilities, a device assembly building and a new launch facility.

In the UK, the company plans to close its Grimsby manufacturing site by 2020, affecting some 395 local employees.

Novarits’ UK country president Haseeb Ahmad said the decision was not linked to Brexit, and that "Novartis remains committed to the UK and believes that the UK is a world leader in life sciences".

The company says it will explore options for the site, including divestment, which could potentially allow the facility to stay open, and will consult closely and offer support to employees.

Article by
Andrew McConaghie

25th September 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics